Aligos Therapeutics, Inc.

NASDAQ:ALGS

9.48 (USD) • At close November 4, 2024
Bedrijfsnaam Aligos Therapeutics, Inc.
Symbool ALGS
Munteenheid USD
Prijs 9.48
Beurswaarde 58,441,802
Dividendpercentage 0%
52-weken bereik 6.76 - 30
Industrie Biotechnology
Sector Healthcare
CEO Dr. Lawrence M. Blatt MBA, Ph.D.
Website https://www.aligos.com

An error occurred while fetching data.

Over Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184,

Vergelijkbare Aandelen

Reneo Pharmaceuticals, Inc. logo

Reneo Pharmaceuticals, Inc.

RPHM

18.2 USD

Vaccinex, Inc. logo

Vaccinex, Inc.

VCNX

3.24 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.519 USD

Daxor Corporation logo

Daxor Corporation

DXR

9.133 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

3.74 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)